"Working to improve the health of kidney patients world-wide"
UKCRN ID 2542, NCT00125593, EudraCT 2004-001156-37, ISRCTN 54137607
Taking the combination of simvastatin and ezetimibe long-term reduced the risk of heart attacks, strokes and operations to open blocked arteries by about one quarter in people with chronic kidney disease, irrespective of the severity of their disease.
This combination treatment reduced risk safely, and may be particularly good for kidney patients as it avoids the possibility of side-effects with high statin doses.
Information for SHARP UK trial participants regarding use of registry data
“This is excellent news for patients who have kidney disease. It was already known that cholesterol-lowering could reduce the risk of heart attacks, strokes and the need for surgery to unblock arteries in people with normal kidney function. But, this trial now shows that cholesterol-lowering has similar effects in people with chronic kidney disease. Taking simvastatin plus ezetimibe long-term would avoid around one quarter of heart attacks, strokes and operations to unblock arteries, leading to their prevention in at least 250,000 people with kidney disease worldwide each year.”